Company intelligence / Profile preview

Sistemic

Ownership: Private
Development stage: Commercial

Overview

Sistemic develops microRNA-based diagnostic assays and analytical platforms to support the pharmaceutical, biotechnology, and cell/gene therapy sectors. Their flagship product suite includes miRNA profiling tools for characterizing stem cells and other cellular therapies—enabling assessment of identity, purity, potency, safety—and supporting quality control in manufacturing. They also offer predictive toxicology services using miRNA signatures. Their technology is used globally by leading companies in regenerative medicine to accelerate development of novel therapies[1][3][4].

Modalities: Diagnostic assay (microRNA-based)Cell therapy characterization tools
Industry: Molecular Diagnostics

Partnerships

RoosterBio Inc (collaboration to advance MSC regenerative technology)

Beyond the preview

Go deeper on Sistemic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sistemic.

Explore the full profile